- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05104567
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)
A Phase 2 Non-randomized, Open-label, Multi-cohort, Multi-center Study Assessing the Clinical Benefit of SAR444245 (THOR-707) Combined With Other Anticancer Therapies for the Treatment of Participants With Advanced and Metastatic Gastrointestinal Cancer
The study is a phase 2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) combined with other anticancer therapies for the treatment of participants aged 18 years and older with advanced and metastatic gastrointestinal cancer. This study is structured as a master protocol for the investigation of SAR444245 with other anticancer therapies.
Sub study 01 - Cohort A aims to establish proof-of-concept that combining the non-alpha-IL2 SAR444245 with the anti-PD1 antibody pembrolizumab will result in a significant increase in the percentage of patients experiencing an objective response in the setting of advanced unresectable or metastatic esophageal squamous cell carcinoma (ESCC).
Sub study 02 - Cohort B1, B2 and B3 would focus on non MSI-H tumors with a large unmet need to establish proof-of-concept that combining the non-alpha-IL2 SAR444245 with the anti-PD1 antibody pembrolizumab will result in a significant increase in the percentage of patients experiencing an objective response in the setting of advanced unresectable or metastatic gastric cancer or gastro-esophageal junction adenocarcinoma (GC/GEJ), especially with low PD-L1 expression or after progression on prior PD1/PD-L1-based regimens.
Sub study 03 - Cohort C aims to establish proof-of-concept that combining the non-alpha-IL2 SAR444245 with the anti-PD1 antibody pembrolizumab will result in a significant increase in the percentage of patients experiencing an objective response in participants with advanced unresectable or metastatic HCC who relapsed on prior PD1/PD-L1-based regimens.
Sub study 04 - Cohort D1 and D2 aims to establish proof-of-concept that combining the non-alpha-IL2 SAR444245 with either the anti-PD1 antibody pembrolizumab or with the anti-EGFR IgG1 antibody cetuximab will result in a significant increase in the percentage of patients experiencing an objective response in the setting of advanced unresectable or metastatic colorectal cancer (mCRC).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Bruxelles, Belgium, BE-1200
- Investigational Site Number : 0560002
-
Edegem, Belgium, 2650
- Investigational Site Number : 0560003
-
Leuven, Belgium, 3000
- Investigational Site Number : 0560001
-
-
-
-
Reg Metropolitana De Santiago
-
Santiago, Reg Metropolitana De Santiago, Chile, 8420383
- Investigational Site Number : 1520001
-
-
-
-
-
Wuhan, China, 430022
- Investigational Site Number : 1560002
-
-
-
-
-
Bordeaux, France, 33075
- Investigational Site Number : 2500004
-
Brest, France, 29200
- Investigational Site Number : 2500006
-
Paris, France, 75015
- Investigational Site Number : 2500002
-
Poitiers, France, 86021
- Investigational Site Number : 2500005
-
Villejuif, France, 94800
- Investigational Site Number : 2500001
-
-
-
-
-
Milano, Italy, 20133
- Investigational Site Number : 3800002
-
Milano, Italy, 20132
- Investigational Site Number : 3800003
-
-
Lombardia
-
Rozzano, Lombardia, Italy, 20089
- Investigational Site Number : 3800001
-
-
-
-
Seoul-teukbyeolsi
-
Seoul, Seoul-teukbyeolsi, Korea, Republic of, 03722
- Investigational Site Number : 4100004
-
Seoul, Seoul-teukbyeolsi, Korea, Republic of, 03080
- Investigational Site Number : 4100002
-
Seoul, Seoul-teukbyeolsi, Korea, Republic of, 05505
- Investigational Site Number : 4100001
-
Seoul, Seoul-teukbyeolsi, Korea, Republic of, 06351
- Investigational Site Number : 4100003
-
-
-
-
-
Amsterdam, Netherlands, 1081 HV
- Investigational Site Number : 5280001
-
Rotterdam, Netherlands, 3015 GD
- Investigational Site Number : 5280003
-
-
-
-
Barcelona [Barcelona]
-
Barcelona, Barcelona [Barcelona], Spain, 08035
- Investigational Site Number : 7240002
-
Barcelona, Barcelona [Barcelona], Spain, 08036
- Investigational Site Number : 7240006
-
-
Cantabria
-
Santander, Cantabria, Spain, 39008
- Investigational Site Number : 7240005
-
-
Madrid, Comunidad De
-
Madrid, Madrid, Comunidad De, Spain, 28027
- Investigational Site Number : 7240101
-
Madrid / Madrid, Madrid, Comunidad De, Spain, 28007
- Investigational Site Number : 7240003
-
Madrid / Madrid, Madrid, Comunidad De, Spain, 28050
- Investigational Site Number : 7240004
-
-
Navarra
-
Pamplona, Navarra, Spain, 31008
- Investigational Site Number : 7240001
-
-
-
-
California
-
Duarte, California, United States, 91010
- City of Hope Site Number : 8400007
-
-
Florida
-
Orlando, Florida, United States, 32804
- AdventHealth Orlando Site Number : 8400005
-
-
Washington
-
Seattle, Washington, United States, 98115
- Seattle Cancer Care Alliance Site Number : 8400009
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participant must be ≥18 years of age (or country's legal age of majority if >18 years), at the time of signing the informed consent.
Participants with:
- Sub-study01: Histologically or cytologically confirmed diagnosis of advanced unresectable or metastatic esophageal cancer of the squamous cell carcinoma subtype.
- Sub-study02: Histologically or cytologically confirmed diagnosis of advanced unresectable or metastatic GC or Siewert Type 2 & 3 GEJ.
- Sub-study03: Histologically or cytologically confirmed diagnosis of advanced unresectable or metastatic hepatocellular carcinoma (HCC), or clinically by AASLD criteria in cirrhotic patients.
- Sub-study04: Histologically or cytologically confirmed diagnosis of advanced unresectable or mCRC. Only patients with non-MSI-H disease are eligible.
- Participants (all sub-studies) must have at least one measurable lesion.
- Mandatory baseline biopsy for the first 20 participants to enroll in sub-study01, sub-study02 and sub-study04. On-treatment biopsy for at least 20 participants in sub-study04. On-treatment biopsies are otherwise optional per Investigator's discretion for the other cohorts.
Females are eligible to participate if they are not pregnant or breastfeeding, not a woman of childbearing potential (WOCBP) or are a WOCBP that agrees:
- to use approved contraception method and submit to regular pregnancy testing prior to treatment and for at least 120 days (for Cohort A, B1, B2, B3, C, and D1) or 60 days (for Cohort D2) [corresponding to the time needed to eliminate any study intervention(s)].
- and to refrain from donating or cryopreserving eggs for 120 days after discontinuing study treatment.
- Males are eligible to participate if they agree to refrain from donating or cryopreserving sperm, and either abstain from heterosexual intercourse OR use approved contraception during study treatment and for at least 3 days [corresponding to time needed to eliminate SAR444245] after the last dose of SAR444245.
- Capable of giving signed informed consent.
Exclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status of ≥2.
- Poor organ function.
- Active brain metastases or leptomeningeal disease.
- History of allogenic or solid organ transplant.
- Last administration of prior antitumor therapy or any investigational treatment within 28 days or less than 5 times the half-life, whichever is shorter; major surgery within 28 days prior to first IMP administration.
- Comorbidity requiring corticosteroid therapy (>10 mg prednisone/day or equivalent) within 2 weeks of IMP initiation. Inhaled or topical steroids are permitted, provided that they are not for treatment of an autoimmune disorder. Participants who require a brief course of steroids (eg, as prophylaxis for imaging studies due to hypersensitivity to contrast agents) are not excluded).
- Antibiotic use (excluding topical antibiotics) ≤14 days prior to first dose of IMP.
- Severe or unstable cardiac condition within 6 months prior to starting study treatment.
- Active, known, or suspected autoimmune disease that has required systemic treatment in the past 2 years.
- Participants with baseline SpO2 ≤92% (without oxygen therapy). - Participant has received prior IL2-based anticancer treatment.
- Participants on sub-study02 cohort B1 and B2 or sub-study 04 - cohort D1 with prior treatment with an agent that blocks the PD-1/PD-L1 pathway.
- Receipt of a live-virus or live attenuated-virus vaccination within 28 days of planned treatment start. Seasonal flu vaccines that do not contain live virus are permitted.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort A (Sub-study 01): 2-3L ESCC Post PD-1/PD-L1
SAR444245 and pembrolizumab are administered every 3 weeks on Day 1 of each cycle (21 days per cycle) for up to 35 cycles.
|
Solution for infusion: intravenous infusion
Solution for infusion: intravenous infusion
Other Names:
|
Experimental: Cohort B1 (Sub-study 02): 1-3L GC/GEJ PD1/PD-L1 naïve non-MSI-H CPS ≥1
SAR444245 and pembrolizumab are administered every 3 weeks on Day 1 of each cycle (21 days per cycle) for up to 35 cycles.
|
Solution for infusion: intravenous infusion
Solution for infusion: intravenous infusion
Other Names:
|
Experimental: Cohort B2 (Sub-study 02): 1-3L GC/GEJ PD1/PD-L1 naïve non-MSI-H CPS < 1
SAR444245 and pembrolizumab are administered every 3 weeks on Day 1 of each cycle (21 days per cycle) for up to 35 cycles.
|
Solution for infusion: intravenous infusion
Solution for infusion: intravenous infusion
Other Names:
|
Experimental: Cohort B3 (Sub-study 02): 2-4L GC/GEJ Post PD1/PD-L1 non-MSI-H
SAR444245 and pembrolizumab are administered every 3 weeks on Day 1 of each cycle (21 days per cycle) for up to 35 cycles.
|
Solution for infusion: intravenous infusion
Solution for infusion: intravenous infusion
Other Names:
|
Experimental: Cohort C (Sub-study 03): 2-3L HCC Post PD-1/PD-L1
SAR444245 and pembrolizumab are administered every 3 weeks on Day 1 of each cycle (21 days per cycle) for up to 35 cycles.
|
Solution for infusion: intravenous infusion
Solution for infusion: intravenous infusion
Other Names:
|
Experimental: Cohort D1 (Sub-study 04): 3-6L CRC non-MSI-H any RAS
SAR444245 and pembrolizumab are administered every 3 weeks on Day 1 of each cycle (21 days per cycle) for up to 35 cycles.
|
Solution for infusion: intravenous infusion
Solution for infusion: intravenous infusion
Other Names:
|
Experimental: Cohort D2 (Sub-study 04): 3-6L CRC non-MSI-H RAS wild type
SAR444245 is administered every 3 weeks on Day 1 of each cycle (21 days per cycle) and cetuximab is administered on Day 1, Day 8 and Day 15 of each cycle until progressive disease.
|
Solution for infusion: intravenous infusion
Solution for infusion: intravenous infusion
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate (ORR)
Time Frame: Baseline to the date of first documentation of progression, assessed approximatively up to 9 months after the first dose of the last patient
|
Objective response rate (ORR) defined as proportion of participants who have a confirmed complete response (CR) or partial response (PR) determined by Investigator per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
|
Baseline to the date of first documentation of progression, assessed approximatively up to 9 months after the first dose of the last patient
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of SAR444245 safety profile when combined with other anti-cancer therapies-Treatment-emergency adverse events (TEAEs)
Time Frame: From 1st IMP dose up to 30 days after the last dose of IMP
|
Incidence TEAEs according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) V 5.0 and American Society for Transplantation and Cellular Therapy (ASTCT) consensus grading
|
From 1st IMP dose up to 30 days after the last dose of IMP
|
Assessment of SAR444245 safety profile when combined with other anti-cancer therapies-Serious Adverse Events (SAEs)
Time Frame: From 1st IMP dose up to 90 days after the last dose of IMP
|
Incidence of SAEs and laboratory abnormalities according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) V 5.0 and American Society for Transplantation and Cellular Therapy (ASTCT) consensus grading
|
From 1st IMP dose up to 90 days after the last dose of IMP
|
Time to response
Time Frame: Baseline to the date of first documentation of progression, assessed approximatively up to 18 months after the last patient-in
|
Defined as the time from the first administration of investigational medicinal product (IMP) to the first tumor assessment at which the overall response was recorded as PR or CR that is subsequently confirmed and determined by Investigator per RECIST 1.1.
|
Baseline to the date of first documentation of progression, assessed approximatively up to 18 months after the last patient-in
|
Duration of response
Time Frame: Baseline to the date of first documentation of progression, assessed approximatively up to 18 months after the last patient-in
|
Defined as the time from first tumor assessment at which the overall response was recorded as CR or PR that is subsequently confirmed until documented progressive disease (PD) determined by Investigator per RECIST 1.1 or death from any cause, whichever occurs first.
|
Baseline to the date of first documentation of progression, assessed approximatively up to 18 months after the last patient-in
|
Clinical benefit rate
Time Frame: Baseline to the date of first documentation of progression, assessed approximatively up to 18 months after the last patient-in
|
Including confirmed Complete Response (CR) or Partial Response (PR) at any time or stable disease (SD) of at least 6 months (determined by investigator per RECIST 1.1)
|
Baseline to the date of first documentation of progression, assessed approximatively up to 18 months after the last patient-in
|
Progression-free survival
Time Frame: Baseline to the date of first documentation of progression, assessed approximatively up to 18 months after the last patient-in
|
Defined as the time from the date of first IMP administration to the date of first documented disease progression determine by Investigator as per RECIST 1.1, or death due to any cause, whichever occurs first
|
Baseline to the date of first documentation of progression, assessed approximatively up to 18 months after the last patient-in
|
Concentrations of SAR444245
Time Frame: At Day 1 and Day 2 of Cycle1, at Day 3 and Day 4 of Cycle 1 (only for intensive PK participants), and at Day 1 of Cycle 2-3-4-6-8-10 + every 4th cycle (each cycle is 21 days), maximum up to approximately 24 months
|
At Day 1 and Day 2 of Cycle1, at Day 3 and Day 4 of Cycle 1 (only for intensive PK participants), and at Day 1 of Cycle 2-3-4-6-8-10 + every 4th cycle (each cycle is 21 days), maximum up to approximately 24 months
|
|
Incidence of anti-drug antibodies (ADAs) against SAR444245
Time Frame: At Day 1 and Day 8 of Cycle1, at Day 1 of Cycle 2-3-4-6-8-10 + every 4th cycle (each cycle is 21 days) and 30 days after last IMP administration, maximum up to approximately 24 months
|
At Day 1 and Day 8 of Cycle1, at Day 1 of Cycle 2-3-4-6-8-10 + every 4th cycle (each cycle is 21 days) and 30 days after last IMP administration, maximum up to approximately 24 months
|
|
Ctrough of infusion of cetuximab
Time Frame: Day 1 of Cycle 1-2-3-4-6-8-10 + every 4th cycle (each cycle is 21 days), maximum up to approximately 24 months
|
Concentration observed just after treatment administration during repeated dosing
|
Day 1 of Cycle 1-2-3-4-6-8-10 + every 4th cycle (each cycle is 21 days), maximum up to approximately 24 months
|
Cend of infusion of cetuximab
Time Frame: Day 1 of Cycle 1-2-3-4-6-8-10 + every 4th cycle (each cycle is 21 days), maximum up to approximately 24 months
|
Day 1 of Cycle 1-2-3-4-6-8-10 + every 4th cycle (each cycle is 21 days), maximum up to approximately 24 months
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Head and Neck Neoplasms
- Esophageal Diseases
- Neoplasms, Squamous Cell
- Carcinoma, Squamous Cell
- Esophageal Neoplasms
- Carcinoma
- Gastrointestinal Neoplasms
- Esophageal Squamous Cell Carcinoma
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Pembrolizumab
- Cetuximab
Other Study ID Numbers
- ACT16902
- U1111-1251-4981 (Registry Identifier: ICTRP)
- 2021-002181-41 (EudraCT Number)
- MK-3475-B78 (Other Identifier: Merck Sharp & Dohme LLC.)
- KEYNOTE-B78 (Other Identifier: Merck Sharp & Dohme LLC.)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatocellular Carcinoma
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditionsUnited States
-
Roswell Park Cancer InstituteMerck Sharp & Dohme LLCActive, not recruitingAdvanced Adult Hepatocellular Carcinoma | Child-Pugh Class A | Stage III Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular...United States
-
Roswell Park Cancer InstituteNational Comprehensive Cancer NetworkCompletedAdvanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular Carcinoma | Stage III... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedUnresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | BCLC Stage C Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC... and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI); Genentech, Inc.RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedUnresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Recurrent Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC v7 and other conditionsUnited States, Canada, Puerto Rico
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingAdvanced Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Metastatic Hepatocellular Carcinoma | BCLC Stage A Hepatocellular CarcinomaUnited States
-
Northwestern UniversityBristol-Myers Squibb; National Cancer Institute (NCI)CompletedStage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular CarcinomaUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science University; American Society of Clinical Oncology; Radiological... and other collaboratorsWithdrawnHepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma AJCC v8 | Stage IB Hepatocellular Carcinoma AJCC v8 | Stage II Hepatocellular Carcinoma AJCC v8 | Stage... and other conditionsUnited States
Clinical Trials on THOR-707
-
SanofiActive, not recruitingMalignant Melanoma | Squamous Cell Carcinoma of SkinGermany, Spain, France, Chile, United States, Australia, Italy
-
SanofiMerck Sharp & Dohme LLCActive, not recruitingDiffuse Large B-cell Lymphoma | Classic Hodgkin LymphomaChile, Spain, Argentina
-
SanofiMerck Sharp & Dohme LLCActive, not recruitingNon-small Cell Lung Cancer | Pleural MesotheliomaChile, Korea, Republic of, Japan, Poland, Spain, United States, Argentina, Australia, France, Italy, Taiwan
-
SanofiMerck Sharp & Dohme LLCActive, not recruitingSquamous Cell Carcinoma of Head and NeckSpain, Italy, United States, Chile, France, Argentina, Canada, Germany, Korea, Republic of, Netherlands, Taiwan
-
Arash Asher, MDThorNot yet recruitingCancer-related Cognitive ImpairmentUnited States
-
Dana-Farber Cancer InstituteCompletedLow Level Light Therapy | Oropharyngeal Mucositis | Myeloablative Hematopoietic Cell TransplantationUnited States
-
University of FloridaNational Institute of Dental and Craniofacial Research (NIDCR)TerminatedPain Related to TMDUnited States
-
Dana-Farber Cancer InstituteTHOR Photomedicine LtdRecruitingOral Mucositis | Myeloablative Allogeneic Hematopoietic Cell Transplantation | Intraoral Photobiomodulation Therapy | Mucosal UlcerUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingGraft-Versus-Host Disease | GVHD | UndefinedUnited States
-
Synthorx, Inc, a Sanofi companyRecruitingMetastasisUnited States, Australia, Singapore, Spain, Argentina, Chile